Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

PIK3CA oncogenic mutations represent a major mechanism of resistance to trastuzumab in HER2/neu overexpressing uterine serous carcinomas.

British journal of cancer - 29 Sept 2015

Black Jonathan D, Lopez Salvatore, Cocco Emiliano, Bellone Stefania, Altwerger Gary, Schwab Carlton L, English Diana P, Bonazzoli Elena, Predolini Federica, Ferrari Francesca, Ratner Elena, Silasi Dan-Arin, Azodi Masoud, Schwartz Peter E, Santin Alessandro D

Abstract excerpt

OBJECTIVES: We evaluated the role of PIK3CA-mutations as mechanism of resistance to trastuzumab in primary HER2/neu-amplified uterine-serous-carcinoma (USC) cell lines. METHODS: Fifteen whole-exome-sequenced USC cell lines were tested for HER2/neu-amplification and PIK3CA-mutations. Four HER2/neu-amplified USC (2-harbouring wild-type-PIK3CA-genes and 2-harbouring oncogenic-PIK3CA-mutations) were evaluated in in...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Class I Phosphatidylinositol 3-Kinases
Share to Cystadenocarcinoma, Serous

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Gene Amplification

Share to Phosphatidylinositol 3-Kinases

Share to Receptor, ErbB-2

Share to Trastuzumab

Share to Uterine Neoplasms

Share to Xenograft Model Antitumor Assays

Source

Open in PubMed Open full text

Identifiers

PMID: 26325104
DOI: 10.1038/bjc.2015.306
PMCID: PMC4651122

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

PIK3CA oncogenic mutations represent a major mechanism of resistance to trastuzumab in HER2/neu overexpressing uterine serous carcinomas.PMID 26325104Read ↗

Dual HER2/PIK3CA Targeting Overcomes Single-Agent Acquired Resistance in HER2-Amplified Uterine Serous Carcinoma Cell Lines In Vitro and In Vivo.Semantic proximity Read ↗

Oncogenic PIK3CA gene mutations and HER2/neu gene amplifications determine the sensitivity of uterine serous carcinoma cell lines to GDC-0980, a selective inhibitor of Class I PI3 kinase and mTOR kinase (TORC1/2).Semantic proximity Read ↗

Concurrent Mutations Associated With Trastuzumab-resistance Revealed by Single Cell SequencingSemantic proximity Read ↗

Concurrent mutations associated with trastuzumab-resistance revealed by single cell sequencing.Semantic proximity Read ↗

PIK3CA-mutations in breast cancer.Semantic proximity Read ↗

Development of the CK-MB-1 trastuzumab-resistant HER2-positive breast cancer cell line and xenograft animal models.Semantic proximity Read ↗

IGF2 Mediates Resistance to Isoform-Selective-Inhibitors of the PI3K in HPV Positive Head and Neck CancerSemantic proximity Read ↗

Targeting FGFR signaling overcomes therapeutic resistance and immune evasion in oncogenic PIK3CA-driven serous-like endometrial cancerSemantic proximity Read ↗

Dual CCNE1/PIK3CA targeting is synergistic in CCNE1-amplified/PIK3CA-mutated uterine serous carcinomas in vitro and in vivo.Semantic proximity Read ↗

Tumour kinome re-wiring governs resistance to palbociclib in oestrogen receptor positive breast cancers, highlighting new therapeutic modalitiesSemantic proximity Read ↗

BRAF, KRAS and PIK3CA Mutation and Sensitivity to Trastuzumab in Breast Cancer Cell Line Model.Semantic proximity Read ↗

HER2 as a target in invasive urothelial carcinoma.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.